microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma

microRNAs are noncoding RNAs inhibiting expression of numerous target genes, and a few have been shown to act as oncogenes or tumor suppressors. We show that microRNA-7 (miR-7) is a potential tumor suppressor in glioblastoma targeting critical cancer pathways. miR-7 potently suppressed epidermal gro...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2008-05, Vol.68 (10), p.3566-3572
Main Authors: Kefas, Benjamin, Godlewski, Jakub, Comeau, Laurey, Li, Yunqing, Abounader, Roger, Hawkinson, Michael, Lee, Jeongwu, Fine, Howard, Chiocca, E Antonio, Lawler, Sean, Purow, Benjamin
Format: Article
Language:English
Subjects:
3' Untranslated Regions
Brain Neoplasms - metabolism
Cell Line, Tumor
Cell Proliferation
Cell Separation
Down-Regulation
Flow Cytometry
Gene Expression Regulation, Neoplastic
Glioblastoma - metabolism
HeLa Cells
Humans
MicroRNAs
Proto-Oncogene Proteins c-akt - metabolism
Transfection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:microRNAs are noncoding RNAs inhibiting expression of numerous target genes, and a few have been shown to act as oncogenes or tumor suppressors. We show that microRNA-7 (miR-7) is a potential tumor suppressor in glioblastoma targeting critical cancer pathways. miR-7 potently suppressed epidermal growth factor receptor expression, and furthermore it independently inhibited the Akt pathway via targeting upstream regulators. miR-7 expression was down-regulated in glioblastoma versus surrounding brain, with a mechanism involving impaired processing. Importantly, transfection with miR-7 decreased viability and invasiveness of primary glioblastoma lines. This study establishes miR-7 as a regulator of major cancer pathways and suggests that it has therapeutic potential for glioblastoma.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.can-07-6639